Tern secures £45,000 bridging loan ahead of open offer

Tern Plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that ahead of the expected receipt of funds from the Company’s underwritten open offer to raise approximately £642,486 (before expenses) announced on 14 July 2025, Tern has received a bridging loan, which has been provided by a vehicle controlled by Al Sisto, non-board CEO of Tern, for the amount of approximately £45,000.

The proceeds of the Bridging Loan will be utilised to fulfil a commitment to one of Tern’s investments, and in doing so will allow Tern to retain its rights in relation to this investment, and for general corporate purposes until the expected receipt of funds from the Underwritten Open Offer, which is expected to be on or around 31 July 2025. As at 30 June 2025, the Company’s unaudited cash balance was approximately £70,000.

The Bridging Loan is an unsecured loan that is repayable on 1 August 2025, which is following the expected receipt of funds from the Underwritten Open Offer. The effective annual interest rate on the Bridging Loan is approximately 12%, which equates to approximately £150 during the term of the loan.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search